(TX_CURR) Number of adults and children currently receiving antiretroviral therapy (ART)

Export Indicator

Number of adults and children currently receiving antiretroviral therapy (ART)
What it measures

This indicator measures the ongoing scale-up and uptake of ART and retention in ART programs as a critical step in the HIV service cascade and assesses progress towards coverage of ART for all eligible HIV-positive individuals when reviewed against the number of PLHIV that are estimated to be eligible for treatment. It allows us to track the response to the epidemic in specific geographic areas and among specific populations as well as at the national level.


Number of adults and children currently receiving antiretroviral therapy (ART)



How to calculate annual total:
This is a snapshot indicator. Results are cumulative at each reporting period.
Method of measurement

This indicator should be collected from facility ART registers/databases, program monitoring tools, and drug supply management systems.

Count the number of adults and children who are currently receiving ART in accordance with the nationally approved treatment protocol (or WHO/UNAIDS standards) at the end of the reporting period.

• Patients on ART who initiated or transferred-in during the reporting period should be counted.
• Patients that pick up several months of antiretroviral drugs at one visit should also be counted as long as they have received enough ARVs to last to the end of the reporting period.
• However, if it is determined that a patient has died, they should immediately be removed from the TX_CURR results.
• HIV-positive pregnant women who are eligible for and are receiving antiretroviral drugs for their own treatment are included. HIV-positive pregnant women initiating lifelong ART through PMTCT (Option B+) will count as “current” on ART under this indicator. These include HIV-infected pregnant women who:
o Have newly initiated ART during the current pregnancy
o Are already on ART at the beginning of the current pregnancy
Patients excluded from the current on ART count are patients who died, stopped treatment, transferred out, or are lost to follow-up. Patients who have not received ARVs within four weeks of their last missed drug pick-up should not be counted. Patients do not need to qualify as lost to follow-up before tracing efforts commence. Efforts to trace patients that have missed a clinical visit or drug pick-up should begin immediately following a missed clinical contact. TX_ML describes the PEPFAR-recommended patient tracing process in more detail.
This indicator should be reported from both PEPFAR-supported sites in the private or public sector. Patients currently receiving treatment from mobile clinics can be reported in two ways. Firstly, if the mobile clinic is associated (receives commodities, reports to, is staff by) a nearby health facility, then these individuals should be reported by that facility. Secondly, if a mobile clinic is stationary for more than 2 reporting periods, it should be added to the PEPFAR facility list with geocodes and data should be reported for this mobile clinic directly.
DO NOT include: Patients who receive ARVs for post-exposure prophylaxis (PEP) or short-term ART only for prevention (PrEP) should not be reported in this indicator.

Reporting level:


How to review for data quality:

• Confirm that TX_CURR ≥ TX_NEW
• Net new of TX_CURR between reporting periods should be less than TX_NEW in that time period
Measurement frequency
Reporting frequency:

Numerator Disaggregations: 

Disaggregate Groups: 

1. Age/Sex [Required]


1. • <1 F/M, 1-4 F/M, 5-9 F/M, 10-14 F/M, 15-19 F/M, 20-24 F/M, 25-29 F/M, 30-34 F/M, 35-39 F/M, 40-44 F/M, 45-49 F/M, 50+ F/M, Unknown Age F/M


Denominator Disaggregations:

Disaggregate Groups: 





Disaggregate descriptions & definitions:

For age /sex disaggregates:

CURRENT is a state defined by treatment status when last seen, so it is expected that characteristics of these clients would be updated each time they are seen by a program. Age represents an individual’s age at the end of the reporting period or when last seen at the facility. For example, a 14-year-old child will be counted as currently receiving treatment in the <15 age category at the end of reporting period “A”. During reporting period “B” the child turns age 15 and so at the end of this reporting period the child will be counted under the 15+ age category.

Explanation of the numerator

Count the number of adults and children who are currently receiving ART.

Further information

Indicator changes (MER 2.0 v2.2 to v2.3):

• Age/sex disaggregates updated.
• Language under the “How to Collect” section updated to clarify which individuals are counted under this indicator.
PEPFAR-support definition:
Standard definition of DSD and TA-SDI used.
Provision of key staff or commodities for PLHIV receiving ART includes: the provision of key staff and/or commodities can include ongoing procurement of critical commodities, such as ARVs, or funding for salaries of HCW who deliver HIV treatment services. Staff who are responsible for the completeness and quality of routine patient records (paper or electronic) can be counted here; however, staff who exclusively fulfill MOH and donor reporting requirements cannot be counted.
Ongoing support for PLHIV receiving ART service delivery improvement includes: clinical mentoring and supportive supervision of staff at HIV sites providing ART, support for quality improvement activities, patient tracking system support, routine support of ART M&E and reporting, commodities consumption forecasting and supply management
Guiding narrative questions:
1. What percentage of clients are picking up their ART drugs on a quarterly basis? On a semi-annual basis?
2. What percentage of clients are being seen for clinical follow-up visits on a quarterly basis? On a semi-annual basis? On an annual basis?
Data Visualization & Use Examples:
Eswatini 95-95-95 Cascade Example:
Population, PLHIV, and TX_CURR by Five-Year Age Band:
Related Indicators
AV.1 PLHIV on ART, 2020, WHO Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management (https://www.who.int/publications/i/item/consolidated-hiv-strategic-information-guidelines).